$STE
STERIS plc Stock $ste

$ste Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000175789824000016 Filed on August 08, 2024

Income Statement

Concept	2024 Q3	2024 Q2	2023 Q2
Revenue	$1.329B	$1.280B	$1.285B
YoY Change	-1.0%	-0.39%	11.07%
Cost Of Revenue	$750.1M	$707.1M	$711.1M
YoY Change	0.17%	-0.56%	11.33%
Gross Profit	$578.8M	$572.4M	$573.5M
YoY Change	-2.48%	-0.18%	10.75%
Gross Profit Margin	43.55%	44.74%	44.64%
Selling, General & Admin	$329.3M	$335.6M	$359.1M
YoY Change	-13.49%	-6.53%	7.3%
% of Gross Profit	56.89%	58.63%	62.61%
Research & Development	$27.03M	$25.57M	$25.50M
YoY Change	-0.05%	0.28%	3.03%
% of Gross Profit	4.67%	4.47%	4.45%
Depreciation & Amortization	$115.3M	$112.7M	$137.9M
YoY Change	-24.32%	-18.29%	-0.68%
% of Gross Profit	19.91%	19.69%	24.05%
Operating Expenses	$359.1M	$386.9M	$384.6M
YoY Change	-11.91%	0.61%	7.0%
Operating Profit	$219.7M	$185.5M	$188.9M
YoY Change	18.19%	-1.78%	19.26%
Interest Expense	-$18.54M	$30.38M	$32.36M
YoY Change	-150.19%	-6.11%	42.72%
% of Operating Profit	-8.44%	16.38%	17.13%
Other Income/Expense, Net	-$24.77M	-$10.27M	-$30.97M
YoY Change	-30.61%	-66.83%	32.09%
Pretax Income	$194.9M	$175.3M	$157.9M
YoY Change	29.79%	10.98%	17.02%
Income Tax	$43.51M	$35.31M	$34.12M
% Of Pretax Income	22.32%	20.15%	21.61%
Net Earnings	$150.0M	$145.4M	$123.6M
YoY Change	30.1%	17.68%	11.05%
Net Earnings / Revenue	11.29%	11.36%	9.62%
Basic Earnings Per Share	$1.52	$1.47	$1.25
Diluted Earnings Per Share	$1.51	$1.46	$1.25
COMMON SHARES
Basic Shares Outstanding	98.62M shares	98.90M shares	98.65M shares
Diluted Shares Outstanding	99.20M shares	99.38M shares	99.24M shares

Balance Sheet

Concept	2024 Q3	2024 Q2	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$172.2M	$198.3M	$208.6M
YoY Change	-19.54%	-4.93%	-34.05%
Cash & Equivalents	$172.2M	$198.3M	$208.6M
Short-Term Investments
Other Short-Term Assets	$153.4M	$151.0M	$166.1M
YoY Change	-22.91%	-9.08%	12.63%
Inventory	$688.9M	$698.6M	$768.8M
Prepaid Expenses
Receivables	$923.3M	$892.6M	$887.8M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$1.938B	$1.940B	$2.031B
YoY Change	-10.86%	-4.47%	9.92%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.930B	$1.834B	$1.921B
YoY Change	10.65%	-4.54%	22.12%
Goodwill	$4.151B	$4.057B	$3.887B
YoY Change	2.75%	4.38%	-10.06%
Intangibles	$2.004B	$2.049B	$2.865B
YoY Change	-34.47%	-28.48%	-10.27%
Long-Term Investments
YoY Change
Other Assets	$60.27M	$63.13M	$80.04M
YoY Change	-17.02%	-21.13%	14.08%
Total Long-Term Assets	$8.304B	$8.168B	$8.753B
YoY Change	-8.81%	-6.68%	-6.28%
TOTAL ASSETS
Total Short-Term Assets	$1.938B	$1.940B	$2.031B
Total Long-Term Assets	$8.304B	$8.168B	$8.753B
Total Assets	$10.24B	$10.11B	$10.78B
YoY Change	-9.21%	-6.27%	-3.61%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$235.1M	$231.7M	$260.7M
YoY Change	-19.94%	-11.11%	13.84%
Accrued Expenses	$307.5M	$286.6M	$332.8M
YoY Change	0.27%	-13.88%	4.76%
Deferred Revenue
YoY Change
Short-Term Debt	$80.00M	$80.00M	$63.44M
YoY Change	12.77%	26.11%	-57.99%
Long-Term Debt Due	$80.00M	$80.00M	$63.44M
YoY Change	12.68%	26.11%	-57.99%
Total Short-Term Liabilities	$805.5M	$834.4M	$886.9M
YoY Change	-7.75%	-5.93%	-2.36%
LONG-TERM LIABILITIES
Long-Term Debt	$2.156B	$2.236B	$2.860B
YoY Change	-35.95%	-21.84%	0.48%
Other Long-Term Liabilities	$74.15M	$72.37M	$859.0M
YoY Change	-3.13%	-91.58%	1075.48%
Total Long-Term Liabilities	$2.230B	$2.308B	$3.719B
YoY Change	-35.22%	-37.94%	27.39%
TOTAL LIABILITIES
Total Short-Term Liabilities	$805.5M	$834.4M	$886.9M
Total Long-Term Liabilities	$2.230B	$2.308B	$3.719B
Total Liabilities	$3.632B	$3.738B	$4.606B
YoY Change	-28.67%	-18.84%	-3.42%
SHAREHOLDERS EQUITY
Retained Earnings	$2.268B	$2.178B	$1.981B
YoY Change	10.87%	9.95%	-3.71%
Common Stock	$4.491B	$4.500B	$4.498B
YoY Change	-0.62%	0.03%	-5.08%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$6.593B	$6.355B	$6.178B
YoY Change
Total Liabilities & Shareholders Equity	$10.24B	$10.11B	$10.78B
YoY Change	-9.21%	-6.27%	-3.61%

Cashflow Statement

Concept	2024 Q3	2024 Q2	2023 Q2
OPERATING ACTIVITIES
Net Income	$150.0M	$145.4M	$123.6M
YoY Change	30.1%	17.68%	11.05%
Depreciation, Depletion And Amortization	$115.3M	$112.7M	$137.9M
YoY Change	-24.32%	-18.29%	-0.68%
Cash From Operating Activities	$250.7M	$303.7M	$281.1M
YoY Change	71.61%	8.04%	21.31%
INVESTING ACTIVITIES
Capital Expenditures	$101.9M	$108.1M	$66.60M
YoY Change	22.32%	62.28%	-42.55%
Acquisitions		$13.66M	$0.00
YoY Change
Other Investing Activities	-$3.460M	$795.9M	$5.000K
YoY Change	-99.34%	15918140.0%	-99.92%
Cash From Investing Activities	-$105.4M	$687.8M	-$66.60M
YoY Change	-82.62%	-1132.84%	-39.14%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-181.0M	-$998.9M	-213.6M
YoY Change	-138.49%	367.58%	51.07%
NET CHANGE
Cash From Operating Activities	250.7M	$303.7M	281.1M
Cash From Investing Activities	-105.4M	$687.8M	-66.60M
Cash From Financing Activities	-181.0M	-$998.9M	-213.6M
Net Change In Cash	-35.59M	-$8.692M	896.0K
YoY Change	-452.39%	-1070.09%	-102.8%
FREE CASH FLOW
Cash From Operating Activities	$250.7M	$303.7M	$281.1M
Capital Expenditures	$101.9M	$108.1M	$66.60M
Free Cash Flow	$148.8M	$195.7M	$214.5M
YoY Change	137.0%	-8.8%	85.24%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q2	us-gaap	Profit Loss ProfitLoss	145541000	usd
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	6315346000	usd
CY2024Q2	us-gaap	Revenues Revenues	1279502000	usd
CY2023Q2	us-gaap	Revenues Revenues	1183386000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Amortization Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Prior Service Cost Credit Tax OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax	-14000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Amortization Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Prior Service Cost Credit Tax OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax	-17000	usd
CY2024Q2	us-gaap	Cost Of Revenue CostOfRevenue	707072000	usd
CY2023Q2	us-gaap	Cost Of Revenue CostOfRevenue	654382000	usd
CY2024Q2	us-gaap	Gross Profit GrossProfit	572430000	usd
CY2023Q2	us-gaap	Gross Profit GrossProfit	529004000	usd
CY2024Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	335626000	usd
CY2023Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	306530000	usd
CY2024Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	25573000	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	24694000	usd
CY2024Q2	us-gaap	Restructuring Costs RestructuringCosts	25700000	usd
CY2023Q2	us-gaap	Restructuring Costs RestructuringCosts	19000	usd
CY2024Q2	us-gaap	Operating Expenses OperatingExpenses	386899000	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	331243000	usd
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	185531000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	197761000	usd
CY2024Q2	us-gaap	Interest Expense InterestExpense	30384000	usd
CY2023Q2	us-gaap	Interest Expense InterestExpense	32357000	usd
CY2024Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1309000	usd
CY2023Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1377000	usd
CY2024Q2	ste	Gain Loss On Sale Of Business Continuing Operations GainLossOnSaleOfBusinessContinuingOperations	18803000	usd
CY2023Q2	ste	Gain Loss On Sale Of Business Continuing Operations GainLossOnSaleOfBusinessContinuingOperations	0	usd
CY2024Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-10272000	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-30980000	usd
CY2024Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	175259000	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	166781000	usd
CY2024Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	35310000	usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	36200000	usd
CY2024Q2	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	139949000	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	130581000	usd
CY2024Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	5592000	usd
CY2023Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-6791000	usd
CY2024Q2	us-gaap	Profit Loss ProfitLoss	145541000	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	123790000	usd
CY2024Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	140000	usd
CY2023Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	236000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	145401000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	123554000	usd
CY2024Q2	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	1.41
CY2023Q2	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	1.32
CY2024Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.06
CY2023Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.07
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.47
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.25
CY2024Q2	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	1.41
CY2023Q2	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	1.31
CY2024Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0.06
CY2023Q2	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.07
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.46
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.25
CY2024Q2	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.52
CY2023Q2	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.47
CY2023Q2	us-gaap	Profit Loss ProfitLoss	123790000	usd
CY2024Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	140000	usd
CY2023Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	236000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	145401000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	123554000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Amortization Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Prior Service Cost Credit Tax OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax	-14000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Amortization Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Prior Service Cost Credit Tax OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax	-17000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Defined Benefit Plans Net Unamortized Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax	-164000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Defined Benefit Plans Net Unamortized Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodNetOfTax	58000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	5751000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	9793000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	5587000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	9851000	usd
CY2024Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	150988000	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	133405000	usd
CY2024Q2	us-gaap	Profit Loss ProfitLoss	145541000	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	123790000	usd
CY2024Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	112698000	usd
CY2023Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	137925000	usd
CY2024Q2	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-22121000	usd
CY2023Q2	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-445000	usd
CY2024Q2	us-gaap	Share Based Compensation ShareBasedCompensation	11460000	usd
CY2023Q2	us-gaap	Share Based Compensation ShareBasedCompensation	11579000	usd
CY2024Q2	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-2151000	usd
CY2023Q2	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-93000	usd
CY2024Q2	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	10960000	usd
CY2023Q2	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	0	usd
CY2024Q2	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	2451000	usd
CY2023Q2	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-1995000	usd
CY2024Q2	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-107683000	usd
CY2023Q2	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-42446000	usd
CY2024Q2	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	34134000	usd
CY2023Q2	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	67956000	usd
CY2024Q2	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-9438000	usd
CY2023Q2	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-14355000	usd
CY2024Q2	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-17122000	usd
CY2023Q2	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-20572000	usd
CY2024Q2	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1560000	usd
CY2023Q2	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	37919000	usd
CY2024Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	303743000	usd
CY2023Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	281129000	usd
CY2024Q2	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	108083000	usd
CY2023Q2	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	66601000	usd
CY2024Q2	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	usd
CY2023Q2	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	5000	usd
CY2024Q2	us-gaap	Proceeds From Divestiture Of Businesses Net Of Cash Divested ProceedsFromDivestitureOfBusinessesNetOfCashDivested	809571000	usd
CY2023Q2	us-gaap	Proceeds From Divestiture Of Businesses Net Of Cash Divested ProceedsFromDivestitureOfBusinessesNetOfCashDivested	0	usd
CY2024Q2	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	13659000	usd
CY2023Q2	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	usd
CY2024Q2	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	687829000	usd
CY2023Q2	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-66596000	usd
CY2024Q2	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	638125000	usd
CY2023Q2	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	15000000	usd
CY2024Q2	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	-253200000	usd
CY2023Q2	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	-144651000	usd
CY2024Q2	us-gaap	Payments Of Merger Related Costs Financing Activities PaymentsOfMergerRelatedCostsFinancingActivities	87000	usd
CY2023Q2	us-gaap	Payments Of Merger Related Costs Financing Activities PaymentsOfMergerRelatedCostsFinancingActivities	89000	usd
CY2024Q2	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	64203000	usd
CY2023Q2	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	8724000	usd
CY2024Q2	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	51436000	usd
CY2023Q2	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	46427000	usd
CY2024Q2	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	2532000	usd
CY2023Q2	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	0	usd
CY2024Q2	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	5587000	usd
CY2023Q2	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	1254000	usd
CY2024Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-998932000	usd
CY2023Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-213637000	usd
CY2024Q2	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-1332000	usd
CY2023Q2	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-639000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-8692000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	257000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	207020000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	208357000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	198328000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	208614000	usd
CY2024Q2	us-gaap	Profit Loss ProfitLoss	145541000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	5587000	usd
CY2024Q2	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	64203000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	17084000	usd
CY2024Q2	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.52
CY2024Q2	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	51436000	usd
CY2024Q2	ste	Noncontrolling Interest Increase From Contributions To Noncontrolling Interest Holders NoncontrollingInterestIncreaseFromContributionsToNoncontrollingInterestHolders	2532000	usd
CY2024Q2	ste	Increase Decrease In Noncontrolling Interests Other IncreaseDecreaseInNoncontrollingInterestsOther	-6000	usd
CY2024Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	6370445000	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	6087172000	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	123790000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	9851000	usd
CY2023Q2	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	8724000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	12834000	usd
CY2023Q2	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0.47
CY2023Q2	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	46427000	usd
CY2023Q2	ste	Increase Decrease In Noncontrolling Interests Other IncreaseDecreaseInNoncontrollingInterestsOther	-124000	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	6178372000	usd
CY2024Q2	us-gaap	Nature Of Operations NatureOfOperations	<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. Nature of Operations and Summary of Significant Accounting Policies</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science products and services around the globe. We offer our Customers a unique mix of innovative products and services. These include: consumable products, such as detergents, endoscopy accessories, barrier products, instruments and tools; services, including equipment installation and maintenance, microbial reduction of medical devices, instrument and scope repair, laboratory testing, and outsourced reprocessing; capital equipment, such as sterilizers, surgical tables, and automated endoscope reprocessors; and connectivity solutions such as operating room (“OR”) integrati</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate and report our financial information in three reportable business segments: Healthcare, Applied Sterilization Technologies ("AST"), and Life Sciences.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Previously, we had four reportable business segments, however, as a result of the divestiture of our Dental segment, Dental is presented as discontinued operations. Historical information has been retrospectively adjusted to reflect these changes for comparability purposes, as required. We describe our business segments in Note 11 titled "Business Segment Information."</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our fiscal year ends on March 31. References in this Quarterly Report to a particular “year” or “year-end” mean our fiscal year. The significant accounting policies applied in preparing the accompanying consolidated financial statements of the Company are summarized below:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interim Financial Statements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We prepared the accompanying unaudited consolidated financial statements of the Company according to accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information and the instructions to the Quarterly Report on Form 10-Q and Rule 10-01 of Regulation S-X. This means that they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Our unaudited interim consolidated financial statements contain all material adjustments (including normal recurring accruals and adjustments) management believes are necessary to fairly state our financial condition, results of operations, and cash flows for the periods presented.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These interim consolidated financial statements should be read together with the consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended March 31, 2024, which was filed with the Securities and Exchange Commission ("SEC") on May 29, 2024. The Consolidated Balance Sheet at March 31, 2024 was derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the consolidation method to report our investment in our subsidiaries. Therefore, the accompanying consolidated financial statements include the accounts of the Company and its wholly-owned and majority-owned subsidiaries. We eliminate intercompany accounts and transactions when we consolidate these accounts. Investments in equity of unconsolidated affiliates, over which the Company has significant influence, but not control, over the financial and operating polices, are accounted for primarily using the equity method. These investments are immaterial to the Company's consolidated financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Discontinued Operations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On April 11, 2024, the Company announced its plan to sell substantially all of the net assets of its Dental segment for total cash consideration of $787,500, subject to customary adjustments, and up to an additional $12,500 in contingent payment should the Dental business achieve certain revenue targets in fiscal 2025. The transaction was structured as an equity sale and closed on May 31, 2024. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A component of an entity is reported in discontinued operations after meeting the criteria for held for sale classification if the disposition represents a strategic shift that has (or will have) a major effect on the entity's operations and financial results. We analyzed the quantitative and qualitative factors relevant to the divestiture of our Dental segment and determined that those conditions for discontinued operations presentation had been met prior to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">March 31, 2024. The Dental segment results of operations were reclassified to income (loss) from discontinued operations in the Consolidated Statements of Income for all periods presented, and we classified the Dental segment's assets and liabilities as held for sale for the year ended March 31, 2024 in the accompanying Consolidated Balance Sheets. Due to the transaction closing in the first quarter of fiscal 2025, the held for sale assets and liabilities were classified as current as of March 31, 2024. Our Consolidated Statements of Cash Flows include the financial results of the Dental segment for all periods presented. For additional information regarding this transaction and its effect on our financial reporting, refer to Note 4 titled, "Discontinued Operations" and Note 11 titled, "Business Segment Information."</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make certain estimates and assumptions when preparing financial statements according to U.S. GAAP that affect the reported amounts of assets and liabilities at the financial statement dates and the reported amounts of revenues and expenses during the periods presented. These estimates and assumptions involve judgments with respect to many factors that are difficult to predict and are beyond our control. Actual results could be materially different from these estimates. We revise the estimates and assumptions as new information becomes available. This means that operating results for the three month period ended June 30, 2024 are not necessarily indicative of results that may be expected for future quarters or for the full fiscal year ending March 31, 2025.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition and Associated Liabilities</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized when obligations under the terms of the contract are satisfied and control of the promised products or services have transferred to the Customer. Revenues are measured at the amount of consideration that we expect to be paid in exchange for the products or services. Product revenue is recognized when control passes to the Customer, which is generally based on contract or shipping terms. Service revenue is recognized when the Customer benefits from the service, which occurs either upon completion of the service or as it is provided to the Customer. Our Customers include end users as well as dealers and distributors who market and sell our products. Our revenue is not contingent upon resale by the dealer or distributor, and we have no further obligations related to bringing about resale. Our standard return and restocking fee policies are applied to sales of products. Shipping and handling costs charged to Customers are included in Product revenues. The associated expenses are treated as fulfillment costs and are included in Cost of revenues. Revenues are reported net of sales and value-added taxes collected from Customers.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have individual Customer contracts that offer discounted pricing. Dealers and distributors may be offered sales incentives in the form of rebates. We reduce revenue for discounts and estimated returns, rebates, and other similar allowances in the same period the related revenues are recorded. The reduction in revenue for these items is estimated based on historical experience and trend analysis to the extent that it is probable that a significant reversal of revenue will not occur. Estimated returns are recorded gross on the Consolidated Balance Sheets.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In transactions that contain multiple performance obligations, such as when products, maintenance services, and other services are combined, we recognize revenue as each product is delivered or service is provided to the Customer. We allocate the total arrangement consideration to each performance obligation based on its relative standalone selling price, which is the price for the product or service when it is sold separately.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payment terms vary by the type and location of the Customer and the products or services offered. Generally, the time between when revenue is recognized and when payment is due is not significant. We do not evaluate whether the selling price contains a financing component for contracts that have a duration of less than one year.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not capitalize sales commissions as substantially all of our sales commission programs have an amortization period of one year or less.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain costs to fulfill a contract are capitalized and amortized over the term of the contract if they are recoverable, directly related to a contract and generate resources that we will use to fulfill the contract in the future. At June 30, 2024, assets related to costs to fulfill a contract were not material to our consolidated financial statements.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 11 titled, "Business Segment Information" for disaggregation of revenue.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Revenues</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenues consist of revenues generated from sales of consumables and capital equipment. These contracts are primarily based on a Customer’s purchase order and may include a Distributor, Dealer or Group Purchasing Organization ("GPO") agreement.</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue for sales of products when control passes to the Customer, which generally occurs either when the products are shipped or when they are received by the Customer. Revenue related to capital equipment products is deferred until installation is complete if the capital equipment and installation are highly integrated and form a single performance obligation.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Service Revenues</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within our Healthcare and Life Sciences segments, service revenues include revenue generated from parts and labor associated with the maintenance, repair and installation of capital equipment. These contracts are primarily based on a Customer’s purchase order and may include a Distributor, Dealer, or GPO agreement. For maintenance, repair and installation of capital equipment, revenue is recognized upon completion of the service. Healthcare service revenues also include outsourced reprocessing services and instrument repairs. Contracts for outsourced reprocessing services are primarily based on an agreement with a Customer, ranging in length from several months to 15 years. Outsourced reprocessing services revenue is recognized ratably over the contract term using a time-based input measure, adjusted for volume and other performance metrics, to the extent that it is probable that a significant reversal of revenue will not occur. Contracts for instrument repairs are primarily based on a Customer’s purchase order, and the associated revenue is recognized upon completion of the repair. </span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also offer preventive maintenance and separately priced extended warranty agreements to our Customers, which require us to maintain and repair products over the duration of the contract. Generally, these contract terms are cancellable without penalty and range from one to five years. Amounts received under these Customer contracts are initially recorded as a service liability and are recognized as service revenue ratably over the contract term using a time-based input measure. </span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within our AST segment, service revenues include contract sterilization and laboratory services. Sales contracts for contract sterilization and laboratory services are primarily based on a Customer’s purchase order and associated Customer agreement, and revenues are generally recognized upon completion of the service.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contract Liabilities</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments received from Customers are based on invoices or billing schedules as established in contracts with Customers. Deferred revenue is recorded when payment is received in advance of performance under the contract. Deferred revenue is recognized as revenue upon completion of the performance obligation, which generally occurs within one year. During the first three months of fiscal 2025, $45,996 of the March 31, 2024 deferred revenue balance was recorded as revenue. During the first three months of fiscal 2024, $42,300 of the March 31, 2023 deferred revenue balance was recorded as revenue.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 8 titled, "Additional Consolidated Balance Sheet Information" for deferred revenue balances.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Service Liabilities</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments received in advance of performance for cancellable preventive maintenance and separately priced extended warranty contracts are recorded as service liabilities. Service liabilities are recognized as revenue as performance is rendered under the contract. </span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 8 titled, "Additional Consolidated Balance Sheet Information" for service liability balances.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Remaining Performance Obligations</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remaining performance obligations reflect only the performance obligations related to agreements for which we have a firm commitment from a Customer to purchase, and exclude variable consideration related to unsatisfied performance obligations. With regard to products, these remaining performance obligations include orders for capital equipment and consumables where control of the products has not passed to the customer. With regard</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to service, these remaining performance obligations primarily include installation, certification, and outsourced reprocessing services.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As of June 30, 2024, the transaction price allocated to remaining performance obligations was approximately $1,499,543. We expect to recognize </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approximately 53% of the transaction price within one year and approximately 38% beyond one year. The remainder has yet to be scheduled for delivery. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Standards Impacting the Company</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recently Issued Accounting Standards Impacting the Company are presented in the following table:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.992%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Standard</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Date of Issuance</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Date of Adoption</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Effect on the financial statements or other significant matters</span></td></tr><tr><td colspan="27" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Standards that have not yet been adopted</span></td></tr><tr style="height:5pt"><td colspan="27" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASU 2023-07 "Segment Reporting (Topic 280)<br/>Improvements to Reportable Segment Disclosures."</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The standard provides guidance to enhance disclosures related to reportable segment expenses, including requirements to disclose significant segment expenses that are regularly provided to the Chief Operating Decision Maker ("CODM"), the title and position of the CODM and a description of how the CODM uses the information to make decisions regarding the allocation of resources. The standard also requires disclosure of certain segment information currently required annually to be reported on an interim basis. The amendments in this standard are effective for annual periods beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024.</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NA</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We are currently assessing the impact of this standard update on our disclosures in the notes to the consolidated financial statements.</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASU 2023-09 "Income Taxes (Topic 740) Improvements to Income Tax Disclosures."</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The standard provides guidance to enhance disclosures related to income taxes paid (net of refunds), requiring disaggregation by federal, state, and foreign, and disclosure of income taxes paid (net of refunds received) by individual jurisdictions that represent greater than 5% of the total. The standard also requires disclosure of income (loss) from continuing operations before income taxes, disaggregated between domestic and foreign, and income tax expense (or benefit) disaggregated by federal, state, and foreign. Finally, the standard removes the requirement for certain disclosures related to changes in unrecognized tax benefits and certain amounts of temporary differences. The amendments in this standard are effective for annual periods beginning after December 15, 2024.</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NA</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">We are currently assessing the impact of this standard update on our disclosures in the notes to the consolidated financial statements.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A detailed description of our significant and critical accounting policies, estimates, and assumptions is included in our consolidated financial statements included in our Annual Report on Form 10-K for the year ended March 31, 2024, which was filed with the SEC on May 29, 2024. Our significant and critical accounting policies, estimates, and assumptions have not changed materially from March 31, 2024.</span></div>
CY2024Q2	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make certain estimates and assumptions when preparing financial statements according to U.S. GAAP that affect the reported amounts of assets and liabilities at the financial statement dates and the reported amounts of revenues and expenses during the periods presented. These estimates and assumptions involve judgments with respect to many factors that are difficult to predict and are beyond our control. Actual results could be materially different from these estimates. We revise the estimates and assumptions as new information becomes available. This means that operating results for the three month period ended June 30, 2024 are not necessarily indicative of results that may be expected for future quarters or for the full fiscal year ending March 31, 2025.</span></div>
CY2024Q2	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	45996000	usd
CY2023Q2	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	42300000	usd
CY2024Q2	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	1499543000	usd
CY2024Q2	us-gaap	Restructuring And Related Cost Expected Number Of Positions Eliminated RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated	300	unit
CY2024Q1	us-gaap	Restructuring Reserve RestructuringReserve	678000	usd
CY2024Q2	us-gaap	Restructuring Reserve Accrual Adjustment1 RestructuringReserveAccrualAdjustment1	24450000	usd
CY2024Q2	us-gaap	Restructuring Reserve Period Increase Decrease RestructuringReservePeriodIncreaseDecrease	-3753000	usd
CY2024Q2	us-gaap	Restructuring Reserve RestructuringReserve	21375000	usd
CY2023Q2	ste	Asset Acquisition Tax Deductible Goodwill Expected AssetAcquisitionTaxDeductibleGoodwillExpected	60000000	usd
CY2024Q2	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	2254000	usd
CY2023Q2	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	2237000	usd
CY2024Q2	ste	Loss Adjustment On Sale LossAdjustmentOnSale	7843000	usd
CY2023Q2	ste	Loss On Classification As Held For Sale LossOnClassificationAsHeldForSale	0	usd
CY2024Q2	us-gaap	Effective Income Tax Rate Reconciliation Disposition Of Business EffectiveIncomeTaxRateReconciliationDispositionOfBusiness	0.214
CY2023Q2	us-gaap	Effective Income Tax Rate Reconciliation Disposition Of Business EffectiveIncomeTaxRateReconciliationDispositionOfBusiness	0.234
CY2024Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	257023000	usd
CY2024Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	245942000	usd
CY2024Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	111297000	usd
CY2024Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	98304000	usd
CY2024Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	372330000	usd
CY2024Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	374182000	usd
CY2024Q2	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	42063000	usd
CY2024Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	43893000	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	698587000	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	674535000	usd
CY2024Q2	us-gaap	Land Land	99000000	usd
CY2024Q1	us-gaap	Land Land	90134000	usd
CY2024Q2	us-gaap	Buildings And Improvements Gross BuildingsAndImprovementsGross	755596000	usd
CY2024Q1	us-gaap	Buildings And Improvements Gross BuildingsAndImprovementsGross	724492000	usd
CY2024Q2	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	1105315000	usd
CY2024Q1	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	1075082000	usd
CY2024Q2	ste	Capitalized Computer Hardware Software Gross CapitalizedComputerHardwareSoftwareGross	256637000	usd
CY2024Q1	ste	Capitalized Computer Hardware Software Gross CapitalizedComputerHardwareSoftwareGross	256671000	usd
CY2024Q2	us-gaap	Materials Supplies And Other MaterialsSuppliesAndOther	700397000	usd
CY2024Q1	us-gaap	Materials Supplies And Other MaterialsSuppliesAndOther	692642000	usd
CY2024Q2	us-gaap	Construction In Progress Gross ConstructionInProgressGross	522825000	usd
CY2024Q1	us-gaap	Construction In Progress Gross ConstructionInProgressGross	500106000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3439770000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3339127000	usd
CY2024Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1605554000	usd
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1573947000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1834216000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1765180000	usd
CY2024Q2	ste	Term Loan Current Portion TermLoanCurrentPortion	0	usd
CY2024Q1	ste	Term Loan Current Portion TermLoanCurrentPortion	41250000	usd
CY2024Q2	ste	Delayed Draw Term Loan Current Portion DelayedDrawTermLoanCurrentPortion	0	usd
CY2024Q1	ste	Delayed Draw Term Loan Current Portion DelayedDrawTermLoanCurrentPortion	44688000	usd
CY2024Q2	us-gaap	Short Term Borrowings ShortTermBorrowings	80000000	usd
CY2024Q1	us-gaap	Short Term Borrowings ShortTermBorrowings	85938000	usd
CY2024Q2	us-gaap	Line Of Credit LineOfCredit	231278000	usd
CY2024Q1	us-gaap	Line Of Credit LineOfCredit	484529000	usd
CY2024Q2	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	16428000	usd
CY2024Q1	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	17988000	usd
CY2024Q2	ste	Term Loan Long Term Portion TermLoanLongTermPortion	0	usd
CY2024Q1	ste	Term Loan Long Term Portion TermLoanLongTermPortion	3750000	usd
CY2024Q2	ste	Delayed Draw Term Loan Long Term Portion DelayedDrawTermLoanLongTermPortion	0	usd
CY2024Q1	ste	Delayed Draw Term Loan Long Term Portion DelayedDrawTermLoanLongTermPortion	548438000	usd
CY2024Q2	us-gaap	Long Term Debt LongTermDebt	2235601000	usd
CY2024Q1	us-gaap	Long Term Debt LongTermDebt	3120162000	usd
CY2024Q2	us-gaap	Debt Longterm And Shortterm Combined Amount DebtLongtermAndShorttermCombinedAmount	2315601000	usd
CY2024Q1	us-gaap	Debt Longterm And Shortterm Combined Amount DebtLongtermAndShorttermCombinedAmount	3206100000	usd
CY2024Q2	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	85059000	usd
CY2024Q1	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	48152000	usd
CY2024Q2	us-gaap	Accrued Vacation Current AccruedVacationCurrent	17078000	usd
CY2024Q1	us-gaap	Accrued Vacation Current AccruedVacationCurrent	16140000	usd
CY2024Q2	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent	28484000	usd
CY2024Q1	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent	61669000	usd
CY2024Q2	us-gaap	Accrued Liabilities For Commissions Expense And Taxes AccruedLiabilitiesForCommissionsExpenseAndTaxes	15666000	usd
CY2024Q1	us-gaap	Accrued Liabilities For Commissions Expense And Taxes AccruedLiabilitiesForCommissionsExpenseAndTaxes	35980000	usd
CY2024Q2	us-gaap	Other Postretirement Benefits Payable Current And Noncurrent OtherPostretirementBenefitsPayableCurrentAndNoncurrent	994000	usd
CY2024Q1	us-gaap	Other Postretirement Benefits Payable Current And Noncurrent OtherPostretirementBenefitsPayableCurrentAndNoncurrent	994000	usd
CY2024Q2	us-gaap	Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Current And Noncurrent PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesCurrentAndNoncurrent	2091000	usd
CY2024Q1	us-gaap	Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Current And Noncurrent PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesCurrentAndNoncurrent	1896000	usd
CY2024Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	149372000	usd
CY2024Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	164831000	usd
CY2024Q2	us-gaap	Deferred Revenue DeferredRevenue	69323000	usd
CY2024Q1	us-gaap	Deferred Revenue DeferredRevenue	70460000	usd
CY2024Q2	ste	Serviceliabilities Serviceliabilities	94301000	usd
CY2024Q1	ste	Serviceliabilities Serviceliabilities	92590000	usd
CY2024Q2	us-gaap	Self Insurance Reserve Current SelfInsuranceReserveCurrent	17431000	usd
CY2024Q1	us-gaap	Self Insurance Reserve Current SelfInsuranceReserveCurrent	13303000	usd
CY2024Q2	us-gaap	Accrued Sales Commission Current And Noncurrent AccruedSalesCommissionCurrentAndNoncurrent	32934000	usd
CY2024Q1	us-gaap	Accrued Sales Commission Current And Noncurrent AccruedSalesCommissionCurrentAndNoncurrent	33277000	usd
CY2024Q2	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	14570000	usd
CY2024Q1	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	15388000	usd
CY2024Q2	us-gaap	Asset Retirement Obligation Current AssetRetirementObligationCurrent	507000	usd
CY2024Q1	us-gaap	Asset Retirement Obligation Current AssetRetirementObligationCurrent	510000	usd
CY2024Q2	ste	Accrued Interest AccruedInterest	18007000	usd
CY2024Q1	ste	Accrued Interest AccruedInterest	11109000	usd
CY2024Q2	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	39490000	usd
CY2024Q1	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	83107000	usd
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	286563000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	319744000	usd
CY2024Q2	us-gaap	Self Insurance Reserve Noncurrent SelfInsuranceReserveNoncurrent	21647000	usd
CY2024Q1	us-gaap	Self Insurance Reserve Noncurrent SelfInsuranceReserveNoncurrent	21646000	usd
CY2024Q2	us-gaap	Other Postretirement Benefits Payable Noncurrent OtherPostretirementBenefitsPayableNoncurrent	5428000	usd
CY2024Q1	us-gaap	Other Postretirement Benefits Payable Noncurrent OtherPostretirementBenefitsPayableNoncurrent	5159000	usd
CY2024Q2	us-gaap	Defined Benefit Pension Plan Liabilities Noncurrent DefinedBenefitPensionPlanLiabilitiesNoncurrent	3024000	usd
CY2024Q1	us-gaap	Defined Benefit Pension Plan Liabilities Noncurrent DefinedBenefitPensionPlanLiabilitiesNoncurrent	2727000	usd
CY2024Q2	us-gaap	Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent	1314000	usd
CY2024Q1	us-gaap	Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent	1321000	usd
CY2024Q2	us-gaap	Accrued Income Taxes Noncurrent AccruedIncomeTaxesNoncurrent	6427000	usd
CY2024Q1	us-gaap	Accrued Income Taxes Noncurrent AccruedIncomeTaxesNoncurrent	6508000	usd
CY2024Q2	us-gaap	Asset Retirement Obligations Noncurrent AssetRetirementObligationsNoncurrent	13249000	usd
CY2024Q1	us-gaap	Asset Retirement Obligations Noncurrent AssetRetirementObligationsNoncurrent	13148000	usd
CY2024Q2	ste	Longtermliabilitiesother Longtermliabilitiesother	21279000	usd
CY2024Q1	ste	Longtermliabilitiesother Longtermliabilitiesother	21037000	usd
CY2024Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	72368000	usd
CY2024Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	71546000	usd
CY2024Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.201
CY2023Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.217
CY2024Q2	us-gaap	Income Tax Examination Estimate Of Possible Loss IncomeTaxExaminationEstimateOfPossibleLoss	12000000	usd
CY2024Q2	ste	Uncertain Tax Liability Resulting From Irs Notice UncertainTaxLiabilityResultingFromIRSNotice	50000000	usd
CY2024Q2	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. Commitments and Contingencies</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are, and will likely continue to be, involved in a number of legal proceedings, government investigations, and claims, which we believe generally arise in the course of our business, given our size, history, complexity, and the nature of our business, products, Customers, regulatory environment, and industries in which we participate. These legal proceedings, investigations and claims generally involve a variety of legal theories and allegations, including, without limitation, personal injury (e.g., slip and falls, burns, vehicle accidents), product liability or regulation (e.g., based on product operation or claimed malfunction, failure to warn, failure to meet specification, or failure to comply with regulatory requirements), product exposure (e.g., claimed exposure to chemicals, gases, asbestos, contaminants, radiation), property damage (e.g., claimed damage due to leaking equipment, fire, vehicles, chemicals), commercial claims (e.g., breach of contract, economic loss, warranty, misrepresentation), financial (e.g., taxes, reporting), employment (e.g., wrongful termination, discrimination, benefits matters), and other claims for damage and relief.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe we have adequately reserved for our current litigation and claims that are probable and estimable, and further believe that the ultimate outcome of these pending lawsuits and claims will not have a material adverse effect on our consolidated financial position or results of operations taken as a whole. Due to their inherent uncertainty, however, there can be no assurance of the ultimate outcome or effect of current or future litigation, investigations, claims or other proceedings (including without limitation the matters discussed below). For certain types of claims, we presently maintain insurance coverage for personal injury and property damage and other liability coverages in amounts and with deductibles that we believe are prudent, but there can be no assurance that these coverages will be applicable or adequate to cover adverse outcomes of claims or legal proceedings against us.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Civil, criminal, regulatory or other proceedings involving our products or services could possibly result in judgments, settlements or administrative or judicial decrees requiring us, among other actions, to pay damages or fines or effect recalls, or be subject to other governmental, Customer or other third party claims or remedies, which could materially affect our business, performance, prospects, value, financial condition, and results of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information regarding these matters, see the following portions of our Annual Report on Form 10-K for the year ended March 31, 2024, which was filed with the SEC on May 29, 2024, Item 1 titled "Business - Information with respect to our Business in General - Government Regulation" and the "Risk Factors" in Item 1A titled "Product and service related regulations and claims."</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, STERIS is also involved in legal proceedings as a plaintiff involving contract, patent protection, and other claims asserted by us. Gains, if any, from these proceedings are recognized when they are realized.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to taxation from United States federal, state and local, and foreign jurisdictions. Tax positions are settled primarily through the completion of audits within each individual jurisdiction or the closing of statutes of limitation. Changes in applicable tax law or other events may also require us to revise past estimates. We describe income taxes further in Note 9 to our consolidated financial statements titled, “Income Taxes” in this Quarterly Report on Form 10-Q.</span></div>
CY2024Q2	us-gaap	Revenues Revenues	1279502000	usd
CY2023Q2	us-gaap	Revenues Revenues	1183386000	usd
CY2024Q2	ste	Amortizationandimpairmentofacquiredintangibleassets Amortizationandimpairmentofacquiredintangibleassets	67661000	usd
CY2023Q2	ste	Amortizationandimpairmentofacquiredintangibleassets Amortizationandimpairmentofacquiredintangibleassets	64092000	usd
CY2024Q2	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	2254000	usd
CY2023Q2	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	2237000	usd
CY2024Q2	ste	Redomiciliaton And Tax Restructuring Costs Ax Restructuring RedomiciliatonAndTaxRestructuringCostsAxRestructuring	518000	usd
CY2023Q2	ste	Redomiciliaton And Tax Restructuring Costs Ax Restructuring RedomiciliatonAndTaxRestructuringCostsAxRestructuring	9000	usd
CY2024Q2	ste	Amortizationofinventoryandpropertystepuptofairvalue Amortizationofinventoryandpropertystepuptofairvalue	1391000	usd
CY2023Q2	ste	Amortizationofinventoryandpropertystepuptofairvalue Amortizationofinventoryandpropertystepuptofairvalue	1622000	usd
CY2024Q2	us-gaap	Restructuring Charges RestructuringCharges	28082000	usd
CY2023Q2	us-gaap	Restructuring Charges RestructuringCharges	19000	usd
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	185531000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	197761000	usd
CY2024Q2	us-gaap	Revenues Revenues	1279502000	usd
CY2023Q2	us-gaap	Revenues Revenues	1183386000	usd
CY2024Q2	us-gaap	Revenues Revenues	1279502000	usd
CY2023Q2	us-gaap	Revenues Revenues	1183386000	usd
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	98869000	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	98708000	shares
CY2024Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	507000	shares
CY2023Q2	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	531000	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	99376000	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	99239000	shares
CY2024Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2024Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q2	ste	Deferred Ordinary Shares DeferredOrdinaryShares	25000	shares
CY2023Q2	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	500000000	usd
CY2024Q2	us-gaap	Stock Repurchase Program Remaining Authorized Repurchase Amount1 StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1	443876000	usd
CY2024Q2	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	251507	shares
CY2024Q2	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	56124000	usd
CY2024Q2	us-gaap	Shares Paid For Tax Withholding For Share Based Compensation SharesPaidForTaxWithholdingForShareBasedCompensation	69780	shares
CY2024Q2	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	10256000	usd
CY2023Q2	us-gaap	Shares Paid For Tax Withholding For Share Based Compensation SharesPaidForTaxWithholdingForShareBasedCompensation	51494	shares
CY2023Q2	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	8724000	usd
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	2028765	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0420
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0357
CY2024Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y10M24D
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0094
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.0108
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.2847
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.2798
CY2024Q2	ste	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate	0.0207
CY2023Q2	ste	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate	0.0222
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1869871	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	168.22
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	206432	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	251.35
CY2024Q2	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	81378	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	81.57
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	654	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	219.97
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	512	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	250.06
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1993759	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	180.32
CY2024Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y3M18D
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	92209000	usd
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1418051	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	157.46
CY2024Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y3M18D
CY2024Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	91771000	usd
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	559526	shares
CY2024Q2	ste	Common Stock Fair Market Value Per Share CommonStockFairMarketValuePerShare	219.54
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	12372000	usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	4831000	usd
CY2024Q2	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	5587000	usd
CY2023Q2	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1254000	usd
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	66.87
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	53.45
CY2024Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	93968000	usd
CY2024Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y9M18D
CY2024Q1	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	15388000	usd
CY2024Q2	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	3456000	usd
CY2024Q2	us-gaap	Standard Product Warranty Accrual Payments StandardProductWarrantyAccrualPayments	4274000	usd
CY2024Q2	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	14570000	usd
CY2024Q2	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	53000	usd
CY2023Q2	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	73000	usd
CY2024Q1	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	11000000	usd
CY2024Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	11204000	usd
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-328657000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	5660000	usd
CY2024Q2	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax	-73000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	5587000	usd
CY2024Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-323070000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-320710000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	10211000	usd
CY2023Q2	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax	-360000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	9851000	usd
CY2023Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-310859000	usd
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001757898-24-000016-index-headers.html	Edgar Link	pending
0001757898-24-000016-index.html	Edgar Link	pending
0001757898-24-000016.txt	Edgar Link	pending
0001757898-24-000016-xbrl.zip	Edgar Link	pending
ex21dayton-equitypurchas.htm	Edgar Link	pending
ex21dayton-equitypurchas001.jpg	Edgar Link	pending
ex21dayton-equitypurchas002.jpg	Edgar Link	pending
ex21dayton-equitypurchas003.jpg	Edgar Link	pending
ex21dayton-equitypurchas004.jpg	Edgar Link	pending
ex21dayton-equitypurchas005.jpg	Edgar Link	pending
ex21dayton-equitypurchas006.jpg	Edgar Link	pending
ex21dayton-equitypurchas007.jpg	Edgar Link	pending
ex21dayton-equitypurchas008.jpg	Edgar Link	pending
ex21dayton-equitypurchas009.jpg	Edgar Link	pending
ex21dayton-equitypurchas010.jpg	Edgar Link	pending
ex21dayton-equitypurchas011.jpg	Edgar Link	pending
ex21dayton-equitypurchas012.jpg	Edgar Link	pending
ex21dayton-equitypurchas013.jpg	Edgar Link	pending
ex21dayton-equitypurchas014.jpg	Edgar Link	pending
ex21dayton-equitypurchas015.jpg	Edgar Link	pending
ex21dayton-equitypurchas016.jpg	Edgar Link	pending
ex21dayton-equitypurchas017.jpg	Edgar Link	pending
ex21dayton-equitypurchas018.jpg	Edgar Link	pending
ex21dayton-equitypurchas019.jpg	Edgar Link	pending
ex21dayton-equitypurchas020.jpg	Edgar Link	pending
ex21dayton-equitypurchas021.jpg	Edgar Link	pending
ex21dayton-equitypurchas022.jpg	Edgar Link	pending
ex21dayton-equitypurchas023.jpg	Edgar Link	pending
ex21dayton-equitypurchas024.jpg	Edgar Link	pending
ex21dayton-equitypurchas025.jpg	Edgar Link	pending
ex21dayton-equitypurchas026.jpg	Edgar Link	pending
ex21dayton-equitypurchas027.jpg	Edgar Link	pending
ex21dayton-equitypurchas028.jpg	Edgar Link	pending
ex21dayton-equitypurchas029.jpg	Edgar Link	pending
ex21dayton-equitypurchas030.jpg	Edgar Link	pending
ex21dayton-equitypurchas031.jpg	Edgar Link	pending
ex21dayton-equitypurchas032.jpg	Edgar Link	pending
ex21dayton-equitypurchas033.jpg	Edgar Link	pending
ex21dayton-equitypurchas034.jpg	Edgar Link	pending
ex21dayton-equitypurchas035.jpg	Edgar Link	pending
ex21dayton-equitypurchas036.jpg	Edgar Link	pending
ex21dayton-equitypurchas037.jpg	Edgar Link	pending
ex21dayton-equitypurchas038.jpg	Edgar Link	pending
ex21dayton-equitypurchas039.jpg	Edgar Link	pending
ex21dayton-equitypurchas040.jpg	Edgar Link	pending
ex21dayton-equitypurchas041.jpg	Edgar Link	pending
ex21dayton-equitypurchas042.jpg	Edgar Link	pending
ex21dayton-equitypurchas043.jpg	Edgar Link	pending
ex21dayton-equitypurchas044.jpg	Edgar Link	pending
ex21dayton-equitypurchas045.jpg	Edgar Link	pending
ex21dayton-equitypurchas046.jpg	Edgar Link	pending
ex21dayton-equitypurchas047.jpg	Edgar Link	pending
ex21dayton-equitypurchas048.jpg	Edgar Link	pending
ex21dayton-equitypurchas049.jpg	Edgar Link	pending
ex21dayton-equitypurchas050.jpg	Edgar Link	pending
ex21dayton-equitypurchas051.jpg	Edgar Link	pending
ex21dayton-equitypurchas052.jpg	Edgar Link	pending
ex21dayton-equitypurchas053.jpg	Edgar Link	pending
ex21dayton-equitypurchas054.jpg	Edgar Link	pending
ex21dayton-equitypurchas055.jpg	Edgar Link	pending
ex21dayton-equitypurchas056.jpg	Edgar Link	pending
ex21dayton-equitypurchas057.jpg	Edgar Link	pending
ex21dayton-equitypurchas058.jpg	Edgar Link	pending
ex21dayton-equitypurchas059.jpg	Edgar Link	pending
ex21dayton-equitypurchas060.jpg	Edgar Link	pending
ex21dayton-equitypurchas061.jpg	Edgar Link	pending
ex21dayton-equitypurchas062.jpg	Edgar Link	pending
ex21dayton-equitypurchas063.jpg	Edgar Link	pending
ex21dayton-equitypurchas064.jpg	Edgar Link	pending
ex21dayton-equitypurchas065.jpg	Edgar Link	pending
ex21dayton-equitypurchas066.jpg	Edgar Link	pending
ex21dayton-equitypurchas067.jpg	Edgar Link	pending
ex21dayton-equitypurchas068.jpg	Edgar Link	pending
ex21dayton-equitypurchas069.jpg	Edgar Link	pending
ex21dayton-equitypurchas070.jpg	Edgar Link	pending
ex21dayton-equitypurchas071.jpg	Edgar Link	pending
ex21dayton-equitypurchas072.jpg	Edgar Link	pending
ex21dayton-equitypurchas073.jpg	Edgar Link	pending
ex21dayton-equitypurchas074.jpg	Edgar Link	pending
ex21dayton-equitypurchas075.jpg	Edgar Link	pending
ex21dayton-equitypurchas076.jpg	Edgar Link	pending
ex21dayton-equitypurchas077.jpg	Edgar Link	pending
ex21dayton-equitypurchas078.jpg	Edgar Link	pending
ex21dayton-equitypurchas079.jpg	Edgar Link	pending
ex21dayton-equitypurchas080.jpg	Edgar Link	pending
ex21dayton-equitypurchas081.jpg	Edgar Link	pending
ex21dayton-equitypurchas082.jpg	Edgar Link	pending
ex21dayton-equitypurchas083.jpg	Edgar Link	pending
ex21dayton-equitypurchas084.jpg	Edgar Link	pending
ex21dayton-equitypurchas085.jpg	Edgar Link	pending
ex21dayton-equitypurchas086.jpg	Edgar Link	pending
ex21dayton-equitypurchas087.jpg	Edgar Link	pending
ex21dayton-equitypurchas088.jpg	Edgar Link	pending
ex21dayton-equitypurchas089.jpg	Edgar Link	pending
ex21dayton-equitypurchas090.jpg	Edgar Link	pending
ex21dayton-equitypurchas091.jpg	Edgar Link	pending
ex21dayton-equitypurchas092.jpg	Edgar Link	pending
ex21dayton-equitypurchas093.jpg	Edgar Link	pending
ex21dayton-equitypurchas094.jpg	Edgar Link	pending
ex21dayton-equitypurchas095.jpg	Edgar Link	pending
ex21dayton-equitypurchas096.jpg	Edgar Link	pending
ex21dayton-equitypurchas097.jpg	Edgar Link	pending
ex21dayton-equitypurchas098.jpg	Edgar Link	pending
ex21dayton-equitypurchas099.jpg	Edgar Link	pending
ex21dayton-equitypurchas100.jpg	Edgar Link	pending
ex21dayton-equitypurchas101.jpg	Edgar Link	pending
ex21dayton-equitypurchas102.jpg	Edgar Link	pending
ex21dayton-equitypurchas103.jpg	Edgar Link	pending
ex21dayton-equitypurchas104.jpg	Edgar Link	pending
ex21dayton-equitypurchas105.jpg	Edgar Link	pending
ex21dayton-equitypurchas106.jpg	Edgar Link	pending
ex21dayton-equitypurchas107.jpg	Edgar Link	pending
ex21dayton-equitypurchas108.jpg	Edgar Link	pending
ex21dayton-equitypurchas109.jpg	Edgar Link	pending
ex21dayton-equitypurchas110.jpg	Edgar Link	pending
ex21dayton-equitypurchas111.jpg	Edgar Link	pending
ex21dayton-equitypurchas112.jpg	Edgar Link	pending
ex21dayton-equitypurchas113.jpg	Edgar Link	pending
ex21dayton-equitypurchas114.jpg	Edgar Link	pending
ex21dayton-equitypurchas115.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
ste-20240630.htm	Edgar Link	pending
ste-20240630.xsd	Edgar Link	pending
ste6302024ex151.htm	Edgar Link	pending
ste6302024ex311.htm	Edgar Link	pending
ste6302024ex312.htm	Edgar Link	pending
ste6302024ex321.htm	Edgar Link	pending
ste-20240630_def.xml	Edgar Link	unprocessable
ste-20240630_lab.xml	Edgar Link	unprocessable
ste-20240630_pre.xml	Edgar Link	unprocessable
ste-20240630_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable
ste-20240630_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$STE
STERIS plc Stock $ste

2024 Q3 Form 10-Q Financial Statement

#000175789824000016 Filed on August 08, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$STE STERIS plc Stock $ste

2024 Q3 Form 10-Q Financial Statement

#000175789824000016 Filed on August 08, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$STE
STERIS plc Stock $ste